NCT03089203 2026-02-23
CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer
University of Pennsylvania
Phase 1 Active not recruiting
Clinical Trials
11 trialsNCT01140373 2026-01-15
Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT06094842 2025-04-01
Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer
Fred Hutchinson Cancer Center
Phase 1 Withdrawn
NCT04633148 2024-04-23
Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker
AvenCell Therapeutics, Inc.
Phase 1 Terminated
NCT02995330 2024-02-13
Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT03861403 2023-11-30
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Leap Therapeutics, Inc.
Phase 1 Terminated
NCT05732948 2023-11-29
PD-1 Silent PSMA/PSCA Targeted CAR-T for the Treatment of Prostate Cancer
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1 Unknown
NCT02390063 2020-02-10
Vaccination in Prostate Cancer (VANCE)
University of Oxford
Phase 1 Completed
NCT02423928 2019-10-25
CryoIT
Alden Cancer Therapy II
Phase 1 Completed
NCT01303705 2018-08-29
Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer
Providence Health & Services
Phase 1 Completed
NCT00381173 2013-05-14
A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing
Eisai Inc.
Phase 1 Completed